Preprint / Version 1

Use of Immunotherapy in Lung Adenocarcinoma

##article.authors##

  • S. Kaarthiga student

DOI:

https://doi.org/10.58445/rars.1099

Keywords:

Immunotherapy, Adenocarcinoma, Lungs

Abstract

This paper discusses the most common lung cancer amongst cased worldwide: lung adenocarcinoma. It explores current research being conducted when exploring possibly biomarkers that could indicate tumor formation or therapies for personalized treatments.

References

Antoni Ribas; Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov 1 September 2015; 5 (9): 915–919. https://doi.org/10.1158/2159-8290.CD-15-0563

Sandlin CW, Gu S, Xu J, Deshpande C, Feldman MD, Good MC. Epithelial cell size dysregulation in human lung adenocarcinoma. PLoS One. 2022 Oct 6;17(10):e0274091. doi: 10.1371/journal.pone.0274091. PMID: 36201559; PMCID: PMC9536599.

L Succony, DM Rassl, AP Barker, FM McCaughan, RC Rintoul, Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies, Cancer Treatment Reviews, Volume 99, 2021, 102237, ISSN 0305-7372, https://doi.org/10.1016/j.ctrv.2021.102237.

Inamura K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. International Journal of Molecular Sciences. 2018; 19(4):1259. https://doi.org/10.3390/ijms19041259

D Jingsi, L Bingjie, L Dan , Z Qinghua, H Depei; Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing; Frontiers in Pharmacology; 2019 Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00230

Rendon A, Rayi A. Nivolumab. [Updated 2022 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567801/

Additional Files

Posted

2024-04-20

Categories

License

Copyright (c) 2024 S. Kaarthiga

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license